A share price of Vertex Pharmaceuticals, Inc [VRTX] is currently trading at $484.24, up 0.81%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The VRTX shares have gain 4.68% over the last week, with a monthly amount glided 13.14%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] stock has seen the most recent analyst activity on February 12, 2025, when Canaccord Genuity upgraded its rating to a Hold and also boosted its price target to $424 from $408. Previously, Canaccord Genuity upgraded its rating to Hold on February 11, 2025. On January 30, 2025, downgrade downgraded it’s rating to Equal Weight but maintained its price target of $460 on the stock. H.C. Wainwright reiterated its Buy rating and decreased its price target to $535 on December 20, 2024. Oppenheimer downgraded its rating to a Perform. Jefferies upgraded its rating to Buy for this stock on December 09, 2024, and upped its price target to $550. In a note dated November 14, 2024, Citigroup initiated an Buy rating and provided a target price of $575 on this stock.
Vertex Pharmaceuticals, Inc experienced fluctuations in its stock price throughout the past year between $377.85 and $519.88. Currently, Wall Street analysts expect the stock to reach $494.56 within the next 12 months. Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] shares were valued at $484.24 at the most recent close of the market. An investor can expect a potential return of 2.13% based on the average VRTX price forecast.
Analyzing the VRTX fundamentals
Trailing Twelve Months sales for Vertex Pharmaceuticals, Inc [NASDAQ:VRTX] were 10.98B which represents 14.56% growth. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.02%, Pretax Profit Margin comes in at 0.02%, and Net Profit Margin reading is -0.05%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.03 and Total Capital is -0.01. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 480.16 points at the first support level, and at 476.08 for the second support level. However, for the 1st resistance point, the stock is sitting at 487.85, and for the 2nd resistance point, it is at 491.46.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Vertex Pharmaceuticals, Inc [NASDAQ:VRTX] is 2.69. Also, the Quick Ratio is 2.35, while the Cash Ratio stands at 1.28. Considering the valuation of this stock, the price to sales ratio is 11.32, the price to book ratio is 7.58.
Transactions by insiders
Recent insider trading involved ALTSHULER DAVID, Officer, that happened on Feb 20 ’25 when 1111.0 shares were purchased. EVP, Chief Reg. & Quality Off., Tatsis Ourania completed a deal on Feb 18 ’25 to sell 244.0 shares. Meanwhile, EVP and Chief Legal Officer Biller Jonathan sold 1657.0 shares on Feb 18 ’25.
